NEW YORK, May 3, 2026, 14:05 (EDT)
- Pfizer and Arvinas picked up FDA approval for Veppanu, their pill for adults dealing with ESR1-mutated, ER-positive/HER2-negative advanced or metastatic breast cancer.
- Pfizer lands a new oncology marker just two days ahead of its planned first-quarter results update.
- But the commercial piece isn’t settled yet. Arvinas and Pfizer say they’ll tap a third-party partner to handle the launch.
Pfizer Inc. and Arvinas scored FDA approval for Veppanu, a breast cancer pill, adding a fresh weapon to Pfizer’s oncology lineup. With this nod, Pfizer gains ground in its push to prove it can replace waning sales from legacy products after the COVID boom.
Pfizer’s upcoming first-quarter earnings, set for Tuesday, put a fresh spotlight on growth prospects, looming patent cliffs, and the payoff from its latest drug pipeline moves. Management fields analyst questions during a call slated for 10 a.m. EDT on May 5.
This comes as big pharma scrambles to bulk up pipelines ahead of looming patent expirations that open the door for cheaper competition. On Friday, Reuters noted Pfizer is under the gun from the so-called patent cliff, with biotech M&A deal value in the first quarter hitting $84 billion.
The FDA granted approval to Veppanu—generic name vepdegestrant—for adults dealing with estrogen receptor-positive, HER2-negative breast cancer that harbors an ESR1 mutation and has progressed after at least one round of endocrine therapy. The green light is specifically for cancers fueled by estrogen, not by HER2, where a particular gene mutation chips away at the effectiveness of standard hormone treatments.
Arvinas and Pfizer picked up the FDA nod earlier than the June 5 target, notching the first-ever approval for a PROTAC—proteolysis-targeting chimera. PROTACs act by flagging harmful proteins in the body so cells can get rid of them.
Regulators signed off after seeing data from the VERITAC-2 study, which enrolled 624 adults. Looking at the 270 patients whose tumors carried ESR1 mutations: Veppanu delivered a median progression-free survival of five months. Fulvestrant, the established injectable hormone therapy, clocked in at 2.1 months.
Arvinas CEO Randy Teel, speaking to Reuters, said the approval hands stage-four breast cancer patients an important new option, describing it as “a new way of hitting disease.” Wedbush’s Robert Driscoll weighed in too, saying Veppanu’s efficacy stacks up against other approved breast cancer drugs, although he flagged the challenge of clear-cut comparisons across trials. He called its tolerability profile “compelling.” Reuters
Erika Hamilton, who leads breast cancer research at the Sarah Cannon Research Institute and served as a principal investigator in the trial, called the drug “another tool in the breast cancer treatment arsenal” for patients who’ve exhausted standard therapies. Arvinas
Competition is already in play. Previous data compared vepdegestrant to AstraZeneca’s Faslodex. As Reuters notes, approved therapies for this advanced breast cancer group feature Eli Lilly’s Verzenio, Pfizer’s Ibrance, and Novartis’ Kisqali.
The commercial direction remains up in the air. Arvinas and Pfizer plan to tap a third-party partner, aiming to get the most out of Veppanu’s market opportunity. Teel told Reuters a commercialization agreement—expected in the next few weeks—should help clear up pricing questions.
Clinical risks are in the mix, too. The FDA label flags QTc interval prolongation—a potential heart rhythm problem—and embryo-fetal toxicity, so risk to unborn babies is on the table. As for overall survival, that data set wasn’t mature yet when progression-free survival was analyzed.
U.S. stock markets were shut on Sunday, leaving Pfizer’s most recent trade on Friday at $26.33, down 37 cents from the previous close. Shares of Arvinas ended Friday at $10.51, a 61-cent bump, following the FDA decision that pushed more attention onto the smaller partner.
